Pulse Biosciences (PLSE) Total Current Liabilities (2015 - 2026)

Pulse Biosciences has reported Total Current Liabilities for 12 years, with the latest figure at $11.0 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 22.28% year-over-year to $11.0 million in Q2 2026; TTM through Jun 2026 was $11.0 million, a 22.28% increase from a year earlier, with the FY2025 full-year figure at $7.9 million, down 21.2% from the prior year.
• Total Current Liabilities was $11.0 million for Q2 2026 at Pulse Biosciences, up from $7.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $11.0 million in Q2 2026, with the low at $5.1 million in Q1 2024.
• Average Total Current Liabilities over 5 years is $7.5 million, with a median of $7.0 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities slipped 27.32% in 2024, then soared 52.73% in 2025.
• Over 5 years, Total Current Liabilities stood at $6.0 million in 2022, then grew by 12.16% to $6.7 million in 2023, then jumped by 49.9% to $10.1 million in 2024, then fell by 21.2% to $7.9 million in 2025, then jumped by 38.56% to $11.0 million in 2026.
• The last three Total Current Liabilities figures came in at $11.0 million (Q2 2026), $7.9 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.